Metabolic syndrome in relation to Barrett's esophagus and esophageal adenocarcinoma: Results from a large population-based case-control study in the Clinical Practice Research Datalink

Cancer Epidemiology

Volumn 42, Issue , 2016, Pages 9-14

  Drahos, Jennifer ^a   Li, Lin ^b   Jick, Susan S ^b   Cook, Michael B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

(MeSH): Barrett esophagus; Esophageal Cancer; Gastroesophageal reflux; Metabolic syndrome X; Obesity

Indexed keywords

CHOLESTEROL;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; ADENOCARCINOMA; CASE CONTROL STUDY; COMPLICATION; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; RISK FACTORS;

EID: 84960414729     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.02.008     Document Type: Article

References (37)

1. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., Sirieix P., Saeed I.T., Burnham W.R., Farthing M.J. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002, 51:316-322.
2. Sihvo E.I., Salminen J.T., Rantanen T.K., Ramo O.J., Ahotupa M., Farkkila M., Auvinen M.I., Salo J.A. Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int. J. Cancer 2002, 102:551-555.
3. Abdel-Latif M.M., Duggan S., Reynolds J.V., Kelleher D. Inflammation and esophageal carcinogenesis. Curr. Opin. Pharmacol. 2009, 9:396-404.
4. Chow W.H., Finkle W.D., McLaughlin J.K., Frankl H., Ziel H.K., Fraumeni J.F. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995, 274:474-477.
5. Cook M.B., Corley D.A., Murray L.J., Liao L.M., Kamangar F., Ye W., Gammon M.D., Risch H.A., Casson A.G., Freedman N.D., Chow W.H., Wu A.H., et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and esophageal adenocarcinoma consortium (BEACON). PloS One 2014, 9:e103508.
6. Lagergren J., Bergstrom R., Lindgren A., Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 1999, 340:825-831.
7. Farrow D.C., Vaughan T.L., Sweeney C., Gammon M.D., Chow W.H., Risch H.A., Stanford J.L., Hansten P.D., Mayne S.T., Schoenberg J.B., Rotterdam H., Ahsan H., et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000, 11:231-238.
8. Corley D.A., Kubo A., Levin T.R., Block G., Habel L., Zhao W., Leighton P., Quesenberry C., Rumore G.J., Buffler P.A. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007, 133:34-41. quiz 311.
9. Kubo A., Cook M.B., Shaheen N.J., Vaughan T.L., Whiteman D.C., Murray L., Corley D.A. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013, 62:1684-1691.
10. Taylor J.B., Rubenstein J.H. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am. J. Gastroenterol. 2010, 105(1729):30-37. quiz 38.
11. Omer Z.B., Ananthakrishnan A.N., Nattinger K.J., Cole E.B., Lin J.J., Kong C.Y., Hur C. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2012, 10:722-727.
12. Mirhafez S.R., Pasdar A., Avan A., Esmaily H., Moezzi A., Mohebati M., Meshkat Z., Mehrad-Majd H., Eslami S., Rahimi H.R., Ghazavi H., Ferns G.A., et al. Cytokine and growth factor profiling in patients with the metabolic syndrome. Br. J. Nutr. 2015, 113:1911-1919.
13. Cowey S., Hardy R.W. The metabolic syndrome: a high-risk state for cancer?. Am. J. Pathol. 2006, 169:1505-1522.
14. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., Williams G.R. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
15. Healy L.A., Ryan A.M., Pidgeon G., Ravi N., Reynolds J.V. Lack of differential pattern in central adiposity and metabolic syndrome in Barrett's esophagus and gastroesophageal reflux disease. Dis. Esophagus: Off. J. Int. Soc. Dis. Esophagus/ISDE 2010, 23:386-391.
16. Ryan A.M., Healy L.A., Power D.G., Byrne M., Murphy S., Byrne P.J., Kelleher D., Reynolds J.V. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann. Surg. 2008, 247:909-915.
17. Leggett C.L., Nelsen E.M., Tian J., Schleck C.B., Zinsmeister A.R., Dunagan K.T., Locke G.R., Wang K.K., Talley N.J., Iyer P.G. Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study. Mayo Clin. Proc. 2013, 88:157-165.
18. Drahos J., Ricker W., Parsons R., Pfeiffer R.M., Warren J.L., Cook M.B. Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-medicare data. J. Clin. Gastroenterol. 2014.
19. Lindkvist B., Johansen D., Stocks T., Concin H., Bjorge T., Almquist M., Haggstrom C., Engeland A., Hallmans G., Nagel G., Jonsson H., Selmer R., et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer 2014, 14:103.
20. Stocks T., Bjorge T., Ulmer H., Manjer J., Haggstrom C., Nagel G., Engeland A., Johansen D., Hallmans G., Selmer R., Concin H., Tretli S., et al. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. Int. J. Epidemiol. 2015, 3.
21. Thrift A.P., Hilal J., El-Serag H.B. Metabolic syndrome and the risk of Barrett's oesophagus in white males. Aliment. Pharmacol. Ther. 2015, 41:1182-1189.
22. Herrett E., Thomas S.L., Schoonen W.M., Smeeth L., Hall A.J. Validation and validity of diagnoses in the General practice research database: a systematic review. Br. J. Clin. Pharmacol. 2010, 69:4-14.
23. Khan N.F., Perera R., Harper S., Rose P.W. Adaptation and validation of the Charlson index for Read/OXMIS coded databases. BMC Family Pract. 2010, 11:1.
24. Boggon R., van Staa T.P., Chapman M., Gallagher A.M., Hammad T.A., Richards M.A. Cancer recording and mortality in the general practice research database and linked cancer registries. Pharmacoepidemiol. and Drug Safety 2013, 22:168-175.
25. Jick S.S., Kaye J.A., Vasilakis-Scaramozza C., Garcia Rodriguez L.A., Ruigomez A., Meier C.R., Schlienger R.G., Black C., Jick H. Validity of the general practice research database. Pharmacotherapy 2003, 23:686-689.
26. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 106: 3143-421.
27. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
28. Hosmer D.W., Lemeshow S. Applied Logistic Regression 2000, 373p. Wiley, New York, xii. 2nd ed.
29. Kallel L., Bibani N., Fekih M., Matri S., Karoui S., Mustapha N.B., Serghini M., Zouiten L., Feki M., Zouari B., Boubaker J., Kaabachi N., et al. Metabolic syndrome is associated with gastroesophageal reflux disease based on a 24-hour ambulatory pH monitoring. Dis. Esophagus: Off. J. Int. Soc. Dis. Esophagus/ISDE 2011, 24:153-159.
30. Lee Y.C., Yen A.M., Tai J.J., Chang S.H., Lin J.T., Chiu H.M., Wang H.P., Wu M.S., Chen T.H. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut 2009, 58:174-181.
31. Krarup A.L., Olesen S.S., Funch-Jensen P., Gregersen H., Drewes A.M. Proximal and distal esophageal sensitivity is decreased in patients with Barrett's esophagus. World J. Gastroenterol.: WJG 2011, 17:514-521.
32. Byrne P.J., Mulligan E.D., O'Riordan J., Keeling P.W., Reynolds J.V. Impaired visceral sensitivity to acid reflux in patients with Barrett's esophagus: the role of esophageal motility*. Dis. Esophagus: Off. J. Int. Soc. Dis. Esophagus/ISDE 2003, 16:199-203.
33. Nguyen T., Khalaf N., Ramsey D., El-Serag H.B. Statin use is associated with a decreased risk of Barrett's esophagus. Gastroenterology 2014, 147:314-323.
34. Iyer P.G., Borah B.J., Heien H.C., Das A., Cooper G.S., Chak A. Association of Barrett's esophagus with type II diabetes mellitus: results from a large population-based case-control study. Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2013, 11:1108-1114. e5.
35. Solaymani-Dodaran M., Logan R.F., West J., Card T. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am. J. Gastroenterol. 2005, 100:2616-2621.
36. Solaymani-Dodaran M., Logan R.F., West J., Card T., Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004, 53:1070-1074.
37. Scuteri A., Laurent S., Cucca F., Cockcroft J., Cunha P.G., Manas L.R., Raso F.U., Muiesan M.L., Ryliskyte L., Rietzschel E., Strait J., Vlachopoulos C., et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur. J. Prev. Cardiol. 2015, 22:486-491.